Fidson Healthcare Plc has announced impressive financial results for the year ended December 31, 2025, with profit for the period surging by 61% to ₦9.31 billion from ₦5.78 billion recorded in the corresponding period of 2024, news.ng reports.
The financial statements were signed by Managing Director/CEO Abiola Adebayo and Finance Director Imokha Ayebae.
The pharmaceutical company’s revenue grew by 41% to ₦119.06 billion, compared to ₦84.19 billion in 2024, driven by strong demand across its product portfolio.
Cost of sales increased proportionally to ₦69.92 billion from ₦49.08 billion, resulting in a gross profit of ₦49.15 billion, up 40% from ₦35.10 billion in the prior year.
Operating profit showed remarkable growth, climbing 59% to ₦20.85 billion from ₦13.13 billion in 2024, despite higher administrative expenses of ₦13.56 billion and selling and distribution expenses of ₦9.97 billion.
The company’s earnings per share improved significantly to 388 kobo from 252 kobo in 2024, representing a 54% increase, which should please shareholders.
On the balance sheet, total assets expanded by 10% to ₦80.45 billion from ₦73.49 billion as of December 2024. Inventories increased to ₦26.34 billion from ₦24.18 billion, while trade and other receivables nearly doubled to ₦11.02 billion from ₦6.21 billion, reflecting the company’s business expansion.
Total equity strengthened to ₦30.78 billion from ₦23.73 billion, representing a 30% year-on-year increase. The company’s issued share capital stood at ₦1.20 billion, with retained earnings of ₦24.74 billion, up from ₦17.74 billion previously.
Current liabilities rose to ₦43.26 billion from ₦39.45 billion, primarily due to increased trade and other payables of ₦8.20 billion and interest-bearing loans and borrowings of ₦10.29 billion.
